Three-dimensional printing technology holds marked promise for the pharmaceutical industry and is now under intense investigation. Most research is aimed at a greater efficiency in printing oral dosage forms using powder bed printing or fused deposition modeling (FDM). Oral dosage forms printed by FDM tend to be hard objects, which reduce the risk of cracking and chipping. However, one challenge in printing oral dosage forms via FDM is achieving rapid drug release, because the materials for FDM are basically thermoplastic polymers with slow drug release properties. In this study, we investigated printing a fast-dissolving oral dosage form by adding sugar alcohol to a poly(vinyl alcohol)-based formulation for FDM. Filaments which contain sugar alcohol were successfully prepared, and objects were printed with them as oral dosage forms by FDM. On drug release testing, a printed oral dosage form in a ring shape which contained 55% maltitol showed a more than 85% drug release in 15 min. In vivo oral absorption of this printed oral dosage form in dogs was comparable to that of a conventional fast-dissolving tablet. Of particular interest, the drug release profile and drug amount of the oral dosage forms can be easily controlled by a change in shape using 3D Computer Aided Design. These characteristics will encourage the prevalence of FDM by the pharmaceutical industry, and contribute to the promotion of personalized medicine.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968038 | PMC |
http://dx.doi.org/10.3390/pharmaceutics15020395 | DOI Listing |
Lasers Med Sci
January 2025
Conservative Dentistry Department and Tissue Engineering Laboratories, Faculty of Dentistry, Alexandria University, Alexandria, Alexandria, Egypt.
The purpose of this study was to compare the penetration of methylene blue (MB) dye after laser irradiation using PIPS (photon-induced photoacoustic streaming) and SWEEPS (shockwave enhanced emission photoacoustic streaming) methods compared to Passive ultrasonic irrigation (PUI) and to study their effect on dentin microhardness. A total of 44 single-rooted human teeth which were extracted for orthodontic or periodontal reasons were used. The teeth were decapitated to standardize roots to 12 mm in length.
View Article and Find Full Text PDFJ Biomed Mater Res B Appl Biomater
February 2025
Department of Operative Dentistry, Endodontics, and Dental Materials, Bauru School of Dentistry, University of São Paulo-USP, Bauru, Brazil.
In the present study, chitosan microspheres (MSCH) loaded with different concentrations of simvastatin (2%, 5%, and 10%) were synthesized as a biomaterial for dentin tissue engineering. The microspheres were prepared by emulsion crosslinking method, and simvastatin was incorporated during the process. The microspheres were then physicochemically and morphologically characterized.
View Article and Find Full Text PDFPharmacol Res Perspect
February 2025
Clinical Pharmacology, Oncology, Pfizer Inc., Boulder, Colorado, USA.
Binimetinib is a MEK1/2 inhibitor particularly active in cells harboring activating mutations in the MAP kinase pathway, especially in BRAF and NRAS. Binimetinib, in combination with encorafenib, has received marketing approval in several jurisdictions for the treatment of patients with BRAF V600E or V600K mutant melanoma. The absorption, distribution, metabolism, and excretion of binimetinib were evaluated by administering a carbon 14-labeled binimetinib 45 mg dose (containing 40 μCi of radiolabeled material) to 6 healthy male participants.
View Article and Find Full Text PDFPharmacol Res Perspect
February 2025
Sumitomo Pharma Switzerland GmbH, Basel, Switzerland.
Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the treatment of endometriosis and uterine fibroids. The aim of this postmarketing study was to determine the pharmacokinetics and quantify the amount of relugolix excreted into breast milk of healthy lactating women. Following a single, oral dose of 40 mg relugolix, breast milk was sampled over 120 h.
View Article and Find Full Text PDFPharmacol Res Perspect
February 2025
CareCeutics LLC, Berwyn, Pennsylvania, USA.
Dersimelagon is a novel investigational orally administered selective agonist of the melanocortin-1 receptor. The drug-drug interaction (DDI) potential of dersimelagon was investigated in both nonclinical (in vitro) and clinical studies. The in vitro inhibition of CYP/UGT isoforms and efflux/uptake transporters by dersimelagon was assessed.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!